

## Mutations in *VHL* and Retinal Hemangioblastoma – an Overview

### Introduction

Retinal hemangioblastomas, also called retinal (capillary) angiomas, may lead to vision loss or even blindness by causing such problems as exudative or tractional retinal detachment, macular edema, or glaucoma. In about 30 to 60% of cases, retinal hemangioblastomas are associated with von Hippel-Lindau disease (VHL), a hereditary cancer syndrome characterized by the often multifocal occurrence of retinal, cerebellar, and/or spinal hemangioblastomas, pheochromocytomas, and renal cell carcinomas (1-5). Retinal hemangioblastoma occurs in about half of all VHL patients and is the presenting symptom in about a third, occurring at a mean age of 25 years and before age 10 years in about 5% of cases (2-7). It is important to identify VHL as the cause of retinal hemangioblastoma, since patients with VHL are likely to develop additional retinal hemangioblastomas as well as other manifestations associated with VHL over time. Once VHL has been diagnosed, annual tumor screening can help to detect neoplasms before they become symptomatic and allow early therapeutic intervention. Early diagnosis of VHL has been shown to increase survival of patients with VHL-associated renal cell carcinoma, one of the leading causes of mortality in VHL (8). Incidence of VHL has been estimated at 1 in 36,000 births (9).

Since VHL has been associated with autosomal dominant mutations in the gene *VHL* (10), genetic testing can confirm a diagnosis of VHL before a characteristic combination of neoplasms has developed. In addition, genetic testing can identify both family members at risk for developing the disease, who should undergo annual tumor screening, and family members who do not carry the familial pathogenic mutations in *VHL* and do not need annual surveillance for tumor development.

### Molecular Pathophysiology

*VHL* codes for the VHL protein, which binds to the transcription factors elongin B and C and acts as a component of an E3-ubiquitin ligase complex involved in targeting hypoxia-inducible factor 1alpha (HIF-1alpha) for degradation (see 4,5 for review). Loss-of-function mutations in *VHL* allow HIF-1alpha to persist in absence of hypoxic conditions and lead to increased transcription of hypoxia-inducible genes, resulting in the overexpression of proteins such as vascular endothelial growth factor and transforming growth factor alpha. VHL protein may also play a role in extracellular matrix formation and cell cycle control. *VHL* is believed to act as a tumor suppressor gene, where defects in both copies of the *VHL* gene within the same cell dramatically increase the risk for certain neoplasms. While in the general population two independent somatic events are necessary to disable both copies of the *VHL* gene in a given cell, only one such somatic event is required in carriers of a germline loss-of-function mutation in *VHL*. Therefore, VHL carriers have a greatly increased risk of developing tumors compared to the general population. This risk is inherited in an autosomal dominant manner.

Of note, certain loss-of-function mutations in *VHL* are associated in a recessive mode of inheritance with congenital polycythemia and may account for up to 50% of congenital polycythemia with normal to elevated level of erythropoietin (11). Risk of VHL-associated tumors is low in patients with congenital polycythemia.

### Clinical Presentation

VHL typically presents in the third decade of life with cerebellar hemangioblastoma, retinal hemangioblastoma, or pheochromocytoma (3-5). Other VHL-associated tumors include spinal hemangioblastoma, renal cell carcinoma, paragangliomas, endolymphatic sac tumors, pancreatic neuroendocrine tumors, and renal, pancreatic, epididymal, and broad ligament cysts. Penetrance of VHL has been

reported to be almost complete by age 65 (12). Based on the risk of pheochromocytoma and renal cell carcinoma, several different subtypes of VHL are distinguished. Type 1 is characterized by a low risk of pheochromocytoma and a high risk of renal cell carcinoma. Type 2 shows a high risk of pheochromocytoma and is further separated into types 2A and 2B, which are characterized by low and high risks of renal cell carcinoma, respectively, and type 2C, in which pheochromocytoma remains the sole manifestation (3-5). Type 1 and type 2B, which share a high risk of renal cell carcinoma, are often associated with large deletions in or truncations of the VHL protein (13). In contrast, types 2A and 2C are usually caused by missense mutations in *VHL*.

## Diagnosis

Clinical diagnosis of VHL is based on the presence of two characteristic tumors or, in the presence of a family history of VHL, occurrence of one characteristic tumor. However, a family history is often difficult to recognize due to the variability in clinical presentation of VHL

both between and within affected families. In addition, up to 20% of VHL occurs in patients without a family history (12). Genetic testing can confirm a diagnosis of VHL after the appearance of only one characteristic tumor and can identify family members at risk for VHL before they become symptomatic. Up to 60% of VHL-associated mutations can be detected by gene sequencing (14). Large deletions, which account for about 40% of mutations, require a different detection technology.

## Treatment

Symptomatic cerebellar and spinal hemangioblastomas, pheochromocytomas, and renal cell carcinomas typically require surgery. Treatment with laser photocoagulation or cryotherapy can prevent vision loss due to retinal hemangioblastomas. Once a diagnosis of VHL or the risk of VHL has been established, the patient should undergo annual tumor surveillance (3-5).

## References

1. Niemela M, Lemeta S, Sainio M, Rauma S, Pukkala E, et al (2000) Hemangioblastomas of the retina: impact of von Hippel-Lindau disease. *Invest Ophthalmol Vis Sci* 41:1909-15.
2. Singh AD, Nouri M, Shields CL, Shields JA, Smith AF (2001) Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. *Ophthalmology* 108:1907-11.
3. Joerger M, Koeberle D, Neumann HPH, Gillesen S (2005) Von Hippel-Lindau disease – a rare disease important to recognize. *Onkologie* 28:159-63.
4. Sims KB (2001) Von Hippel-Lindau disease: gene to bedside. *Curr Opin Neurol* 14:695-703.
5. Richard S, French VHL Study Group (2003) von Hippel-Lindau disease: recent advances and therapeutic perspectives. *Expert Rev Anticancer Ther* 3:215-33.
6. Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, et al (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. *Invest Ophthalmol Vis Sci* 43:3067-74.
7. Schmidt D (2005) Retinal angiomas. *Klin Monatsbl Augenheilkd* 222:90-109.
8. Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER (1998) Molecular genetic analysis of von Hippel-Lindau disease. *J Intern Med* 243:527-33.
9. Maher ER, Iselius L, Yates JR, Littler MD, Benjamin C, et al (1991) Von Hippel-Lindau disease: A genetic study. *J Med Genet* 28:443-447.
10. Latif F, Tory K, Gnarr J, Yao M, Duh FM, et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 260:1317-20.
11. Pastore Y, Jedlickova K, Guan Y, Liu E, et al (2003) Mutations in von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. *Am J Hum Genet* 73:412-19.
12. Cybulski C, Krzystolik K, Murgia A, Gorski B, Debniak T, et al (2002) Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. *J Med Genet* 39:e38 (<http://www.jmedgenet.com/cgi/content/full/39/7/e38>)
13. Gallou C, Chauveau D, Richard S, Joly D, Giraud S, et al (2004) Genotype-phenotype correlations in von Hippel-Lindau families with renal lesions. *Hum Mutat* 24:215-24.

14. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, et al (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat* 12:417-23.